Home » Stocks » MBRX

Moleculin Biotech, Inc. (MBRX)

Stock Price: $0.766 USD -0.024 (-3.04%)
Updated November 24, 3:50 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 47.85M
Revenue (ttm) n/a
Net Income (ttm) -18.51M
Shares Out 62.46M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $0.766
Previous Close $0.790
Change ($) -0.024
Change (%) -3.04%
Day's Open 0.770
Day's Range 0.753 - 0.782
Day's Volume 566,339
52-Week Range 0.323 - 1.970

More Stats

Market Cap 47.85M
Enterprise Value 35.24M
Earnings Date (est) Apr 5, 2021
Ex-Dividend Date n/a
Shares Outstanding 62.46M
Float 51.75M
EPS (basic) -0.33
EPS (diluted) -0.34
FCF / Share -0.32
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.60M
Short Ratio 6.43
Short % of Float 5.02%
Beta 2.20
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.58
Revenue n/a
Operating Income -21.06M
Net Income -18.51M
Free Cash Flow -19.69M
Net Cash 12.61M
Net Cash / Share 0.20
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -45.75%
ROE -110.72%
ROIC 22,997.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(334.73% upside)
Current: $0.766
Target: 3.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-17.52-15.03-8.65-3.88-0.47-1.65
Net Income-13.21-11.88-9.81-3.93-0.37-1.81
Shares Outstanding40.7225.9018.579.836.61-
Earnings Per Share-0.32-0.46-0.53-0.40--
Operating Cash Flow-17.20-12.20-7.32-3.77-0.72-1.35
Capital Expenditures-0.05-0.42-0.03-0.02--
Free Cash Flow-17.25-12.62-7.35-3.79-0.72-1.35
Cash & Equivalents10.747.137.715.010.030.52
Total Debt0.28--0.300.451.63
Net Cash / Debt10.467.137.714.71-0.42-1.10
Book Value15.5714.2717.1214.96-0.74-2.47
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Moleculin Biotech, Inc.
Country United States
Employees 11
CEO Walter V. Klemp

Stock Information

Ticker Symbol MBRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MBRX
IPO Date June 2, 2016


Moleculin Biotech, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. The company has partnerships and collaboration agreement with The University of Texas MD Anderson Cancer Center, Emory University, Mayo Clinic Research Endeavor, The University of Iowa, Medical University of Gdansk, University of Bergen, DERMIN Sp. z o. o., and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.